DOTA-GA(tBu)4 stabilizes the attachment of radiometals to ligands. DOTA-GA(tBu)4 improves the biodistribution of radiolabeled second-generation Affibody molecules by increasing their net negative charge and reducing hepatic uptake, leading to enhanced tumor-to-blood and tumor-to-liver ratios. DOTA-GA(tBu)4 targets HER2-expressing breast and gastrointestinal cancer. [1][2]
Molecular Weight:
700.90
Purity:
99.30
CAS Number:
[306776-79-4]
Formula:
C35H64N4O10
Target:
Radionuclide-Drug Conjugates (RDCs)
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
